Here is information about recent NASPCC webinars. Use the links below to view the recorded webinar and handouts:
“Sexual Side Effects: Prostate Cancer”
with John P. Mulhall, MD, MSc, FECSM, FACS, FRCSI
Recorded November 28, 2023
This Webinar will help Patients engage in better-shared decision-making with their Physicians.
Dr. Mulhall, a native of Dublin, Ireland, is a Board-Certified urologist and a microsurgeon and is the Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan Kettering in New York City. He is also an Adjunct Professor of Urology at Weill Cornell Medical College. His clinical research interests include predictors of post-prostatectomy erectile function recovery, pelvic radiation-associated ED, the development of novel instruments for evaluating sexual function, and the design and conduct of drug trials in sexual medicine.
Link to online video - for the November 28, 2023 webinar "Sexual Side Effects: Prostate Cancer"
Link to online materials for the November 28th webinar - Powerpoint required.
"Second-Generation Anti-Androgens: Managing Side Effects”
with Andrew Armstrong, MD, MSc
Recorded August 23, 2023
Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology, and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, and medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, PARP inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phases 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 200 peer-reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovering science in GU cancers in the laboratory and treatment science in the clinic. As an R01-funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and laboratory training.
Link to online video of the August 23, 2023 webinar...
Link to download the PowerPoint slides from the August 23, 2023 webinar...
“Clinical Trials in Prostate Cancer Using PARP Inhibitors”
with Neeraj Agarwal, MD
Recorded June 15, 2023
This Webinar will help Patients engage in better-shared decision-making with their Physicians.
Dr. Neeraj Aggarwal is a Professor of Medicine and a Presidential-Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI) at the University of Utah. He also directs the Genitourinary Oncology Program and the Center of Investigational Therapeutics (CIT) at the Huntsman Cancer Institute.
Dr. Aggarwal is an internationally-recognized physician-scientist in GU cancers. He has received multiple awards and has served as the overall study chair or steering committee member for many clinical trials. Dr. Aggarwal has authored more than 375 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN and ASCO Guidelines Committees in GU cancers; Chief Editor of the ASCO Daily News; specialty editor for ASCO’s cancer.net site; and is a member of the ASCO Genitourinary Cancers Advisory Panel. He was recently appointed the Senior Director for Clinical Research Innovation at the Huntsman.
Link to online materials - coming soon
“Stereotactic Body Radiotherapy for Prostate Cancer: A 2023 Update for Patients”
with Amar Kishan, MD
Recorded Tuesday, April 25, 2023
This Webinar will help Patients engage in better-shared decision-making with their Physicians.
Dr. Amar Kishan is an Associate Professor, Vice-Chair of Clinical and Translational Research, and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at UCLA and the UCLA Jonsson Comprehensive Cancer Center. He graduated from Berkeley with dual degrees in Molecular and Cell Biology and Public Health. He then earned his Medical Degree from Harvard Medical School, graduating magna cum laude from the joint Harvard-MIT Health Sciences and Technology Program. He trained at Scripps Mercy Hospital in San Diego and then completed his training in radiation oncology at UCLA.
Dr. Kishan specializes in the utilization of radiation to treat genitourinary malignancies, particularly of the prostate and bladder. He has published over 200 manuscripts, including lead authorship publications. He runs an active clinical and translational research program and has led many innovative clinical trials in radiation oncology.
Link to online video recording of the April 25, 2023 webinar...
Link to download the PowerPoint slides from the April 25, 2023 webinar...
“Innovations in Prostate Cancer Care”
with Eric Klein, MD
Recorded: Thursday, September 29, 2022
This Webinar will help patients have better shared decision-making with their physicians.
Dr. Klein is the Emeritus Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine at the Cleveland Clinic. A former President of the Society of Urologic Oncology, Dr. Klein is currently a Fellow in the Distinguished Careers Institute at Stanford University. His clinical and research interests cover all stages of prostate cancer, with a specific interest in genomics and clinical trials. Along with over 700 articles Dr. Klein has authored in the literature as well as 8 books he has either authored or edited; he currently also serves as the Editor-in-Chief of UROLOGY. Dr. Eric Klein’s awards are too numerous to list in this Flyer, but he is beloved by patients and by colleagues as well.
Link to online video recording of the September 29, 2022 webinar...
Link to download the PowerPoint slides from the September 29, 2022 webinar...
“Prostate Cancer in Military Veterans”
with Bruce Montgomery, MD
Recorded Tuesday, June 9, 2022
Dr. Bruce Montgomery is Clinical Director of Genitourinary Oncology at the Seattle Cancer Care Alliance and Professor in the Medical Oncology Division of the University of Washington. He is also an Affiliate Member in the Clinical Research Division of the Fred Hutchinson Cancer Research Center. Dr. Montgomery helps lead the Precision Oncology Program for Cancer of the Prostate Network, a Veterans Affairs/PCF Collaboration. He will speak on Prostate Cancer in Military Veterans, a topic of continuing and growing interest especially with the newer considerations of carcinogenic exposures for certain veterans.
More information coming soon...
“The Path to Cure in Prostate Cancer”
with James L. Gulley, MD, PhD
Recorded Monday, April 18, 2022
James L. Gulley, MD, PhD, is an internationally recognized expert in immunotherapy for cancer. Dr. Gulley serves within the Center for Cancer Research (CCR) of the National Cancer Institute as Chief of the Genitourinary Malignancies Branch (GMB), the Director of the Medical Oncology Service (CCR), and also Head of the Immunotherapy Section within the GMB. He has been instrumental in the clinical development of multiple immunotherapeutic agents and has led multiple first-in-human immunotherapy studies through phase 3 clinical trials.
Link to online video recording of the April 18, 2022 webinar...
“Overview of Prostate Cancer Imaging”
with Thomas Hope MD
Recorded: February 7, 2022
Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is also the Associate Chair for Joint Ventures for Radiology and Chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally, he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors at UCSF.
An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. Join us to hear an Overview of Prostate Cancer Imaging!
Access to the archive recording of the February 7, 2022 webinar
PowerPoint for the February 7, 2022 webinar - PDF
“Everything You Ever Wanted to Ask About Immunotherapy But Didn’t Know How to Ask”
With Saul Priceman, PhD
Recorded: Thursday, November 11, 2021
Saul Priceman, PhD, is an assistant professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer.
Dr. Priceman will discuss and answer questions he hears from patients and others about Immuno-Oncology, an exciting new treatment approach being explored in prostate and other cancers.
Resources
Access to the archive recording of November 11 webinar recording - coming soon
PowerPoint for the November 12 webinar - coming soon
“What’s New in Active Surveillance in 2021”
With Laurence Klotz, MD, FRCSC
Recorded October 12, 2021
Dr. Klotz is Professor, Department of Surgery, University of Toronto; Chief, Division of Urology, Sunnybrook Health Sciences Center; Chair, Canadian Uro-Oncology Group; and NCIC GU Site Group Editor in Chief (founding), Canadian Journal of Urology; Chair, Global GU Oncology Group, and Chair of Prostate Cancer Research at Sunnybrook Health Sciences Centre in Toronto.
Dr. Klotz has a long-standing interest in the conservative management of prostate cancer and is the principal investigator on a number of clinical trials evaluating the role of various interventions and imaging studies in men on active surveillance. He was in the forefront of key opinion leaders looking into Active Surveillance long before it was as widely accepted for early prostate cancer as it is now.
Resources
- Access to the archive recording of October 12 webinar recording
- PowerPoint for the October 12 webinar
“TheraP/VISION Trial on Lutetium-PSMA”
With Michael Hofman, MBBS, FRACP, FAANMS, FICIS, Director of the Prostate Cancer Theranostics and Imaging Center of Excellence (ProsTIC) at
The Peter MacCallum Cancer Center in Melbourne, Australia.
Recorded: August 2, 2021
Professor Michael Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in Oncology. This includes neuroendocrine tumours and hematologic applications; more recently he has focused on improving outcomes for men with prostate cancer. Prof Hofman has a leading academic track record for his specialty, with over 200 peer reviewed manuscripts and book chapters. He has received a number of international awards including the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Image of the Year 2018 and awards for best scientific research at several international conferences. He is a frequent invited speaker at national and international meetings, and was the co-chair of the scientific committee for the 4th World Theranostic World Congress in 2016. In 2015 he was elected a fellow of the International Cancer Imaging Society, one of three Australians recognized by the society. He was a member of the oncology subcommittee of the ongoing MBS Review where he advocates for fair and equitable access to PET scanning for patients with cancer.
Resources
- Access to the archive recording of August 2nd webinar recording
- PowerPoint for the August 2nd webinar
“PARP Inhibition in Prostate Cancer”
With Dr. Charles Ryan, M.D., Director of the Hematology, Oncology, Transplant Division in the Dept. of Medicine at the University of Minnesota
Recorded: July 28, 2021
Charles J Ryan, MD is the Director of the Hematology, Oncology and Transplantation Division in the Dept. of Medicine at the University of Minnesota. He also holds the B.J. Kennedy Chair in Clinical Medical Oncology. He attended the University of Wisconsin Medical School and he trained there, serving as Chief Resident, and at Memorial Sloan-Kettering. He was then on the faculty of UCSF where he served as Program Leader for Genitourinary Medical Oncology and was the Thomas Perkins Distinguished Professor in Cancer Research. Dr. Ryan is internationally recognized for his work focusing on the development of new treatments for advanced prostate cancer, as well as supportive care for men with prostate cancer. He has published over 175 articles and chapters in leading medical journals and has authored “The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In” released in February of 2018. Dr. Ryan is the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national Clinical Trials group.
Resources
“Cabazitaxel in Metastatic Prostate Cancer, with an Update on the CARD Trial”
With Daniel George, M.D., Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine
Recorded: June 10, 2021
Dr. Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology disease-based group and is co-lead of the DCI Center for Prostate and Urologic Cancers. He is an internationally recognized clinical researcher and thought leader in GU Malignancies, with over 200 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU Cancers with an emphasis on signal transduction pathways and cancer disparities. Dr. George is the co-PI of IRONMAN, an international multi-sponsor supported registry in advanced prostate cancer.
Resources
“Critical Aspects of Prostate Cancer Pathology for Patients”
With Jonathan I. Epstein M.D., Professor, Pathology, Oncology, and Urology at Johns Hopkins School of Medicine
Recorded: April 13, 2021
About the Presenter
Dr. Jonathan I. Epstein is a Professor of Pathology, Oncology and Urology at the Johns Hopkins School of Medicine. He also serves as the Director of Surgical Pathology at The Johns Hopkins Hospital.
After obtaining his MD, and following a residency in anatomic pathology at Johns Hopkins and a fellowship in oncological pathology at Memorial Sloan-Kettering Cancer Center in New York, he joined the faculty at Johns Hopkins in 1985. Dr. Epstein is recognized as a leader in the field of urological pathology, lectures widely here and abroad on urologic pathology, and has written 7 books and more than 800 articles on the subject.
Resources
“Use of Genomics to Guide Treatment Decisions after Radical Prostatectomy”
With Ashley Ross, MD, PhD, Associate Professor, Northwestern Feinberg School of Medicine
Recorded: March 10, 2021
About the Presenter
Ashley Ross, MD, PhD is an Associate Professor of Urology at the Northwestern Feinberg School of Medicine. His research and clinical efforts focus on the development, testing and implementation of novel diagnostics and therapeutics with a goal of reducing the suffering from prostate cancer. Prior to joining the Feinberg School of Medicine, Dr. Ross served as director of the Johns Hopkins Urology Prostate Cancer Program, the executive medical director of the Mary Crowley Cancer Research Center, and an associate chair of the US Oncology Genitourinary Research Committee.
Resources
“Immuno-Oncology: Novel Mechanisms of Action in Prostate Cancer”
With Saul Priceman, PhD, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope
Recorded: February 1, 2021
About the Presenter
Dr. Saul Priceman is a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He received his PhD in 2010 from UCLA, and did his post-doctoral training at City of Hope (COH), where he is now an Assistant Professor. The Priceman Lab focuses on translational research relevant to developing innovative cellular immunotherapy for the treatment of solid tumors, including prostate cancer. His research interests are centered on cellular immunotherapy, primarily using Car-T cell therapy.
Dr. Priceman will speak on these modalities and on new mechanisms of action, including the new BiTE mechanism of immuno-oncology. Dr. Priceman has authored or co-authored over 30 publications in the field of cancer immunotherapy, and was interviewed for the November Issue of PROSTATEPEDIA Magazine published by NASPCC, which centered on the topic of Immuno-Oncology and PARP Inhibition.
Resources
“Theranostics in Prostate Cancer*”
With Dr. Michael Morris, Section Head of Prostate Cancer, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center in New York
Recorded: January 11, 2021
* Theranostics describes the combination of using one radioactive drug to diagnose and a second radioactive drug to deliver therapy to treat the main tumor and any metastases
About the Presenter
Dr. Michael Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan- Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
Resources
“Incontinence and Sexual Side Effects of Prostate Cancer Treatment”
With William Brant, MD, FACS, FECSM, Urologist & Men’s Sexual Health Physician in Salt Lake City, Utah
Recorded: Tuesday, December 8, 2020
About the Presenter
Dr. Willam Brant attended Dartmouth College and the University of Washington, and obtained his MD at the University of California, San Diego. He completed residencies in Surgery and Urology at the University of Colorado Health Sciences Center and a fellowship in sexual medicine and surgery at UCSF. Dr. Brant’s practice is dedicated to Men’s Health, with a particular focus on sexual and erectile medicine; male urinary incontinence; penile reconstructive surgery; and prosthetic surgery. His current practice is divided between Summit Urology/Granger Medical Clinic and the Salt Lake City Veterans Affairs Medical Center.
Dr. Brant is a member of the AUA, the Sexual Medicine Society, and the Society of Urologic Prosthetic Surgeons, among others. He has authored over 100 works, including various chapters in 6 textbooks in Urology.
Resources
“The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer”
With Dr. Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University.
Recorded: Wednesday, November 4, 2020
About the Presenter
Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 170 peer reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.
Resources
Sponsor
NASPCC is receiving support for this webinar from Dendreon:
“Immunotherapy and PARP Inhibition”
With Dr. Judd Moul, Professor, Duke University Medical Center.
Recorded: October 5, 2020
About the Presenter
Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.
Dr. Moul serves on the editorial boards of American Journal of Men’s Health, Urology and Prostate Cancer and Prostatic Diseases. He serves on the Executive Committee for the American Joint Commission for Cancer (AJCC). Dr. Moul has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General of the US Army, and the Castle Connolly National Physician of the Year award in 2009. *Dr. Judd Moul is not receiving any compensation for this presentation*
Resources
Sponsor
NASPCC is receiving support for this Webinar from Dendron:
“PSMA Imaging in Prostate Cancer: New Developments”
With Dr. Michael Morris, Clinical Director, Memorial Sloan-Kettering Cancer Center in New York
Recorded: October 1, 2020
About the Presenter
Dr. Michael Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
Resources
Sponsor
This Webinar is sponsored by: Progenics Pharmaceuticals
“Exosome Testing and Liquid Biopsies – Risk Assessment for High-Grade Prostate Cancer: Home or Office Testing”
With Dr. Judd Moul, Professor, Duke University Medical Center.
Recorded: July 29, 2020
About the Presenter
Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.
Resources
- Link to the July 29, 2020 webinar archive recording
- PowerPoint deck from the July 29, 2020 presentation
- Prostate Cancer handout from Prostate Cancer and Prostatic Diseases - PDF
Sponsor
This Webinar is sponsored by: Exosome Diagnostics
Managing the Side Effects of Prostate Cancer and its Treatment: Emotional Distress, Intimacy Issues, Erectile Dysfunction and Incontinence
Recorded February 27, 2020
Sponsored by Boston Scientific.
Presenters
Dr. Krishnan Venkatesan, MD
Director of Urologic Reconstruction, Washington Hospital Center.
A native of Detroit, Dr. Krishnan completed his undergraduate studies at Columbia University in the City of New York before returning home for medical school at Wayne State University. He stayed on at Wayne State for his residency in Urology,which he completed in 2010. He then undertook a fellowship in Genitourinary Reconstruction at the Institute of Urology at University College London and went on to Pune, India to pursue further training in complex urethral reconstruction at the Kulkarni EndoSurgery Institute. Krishnan then moved to Washington, DC to become the Director of Urologic Reconstruction at MedStar Washington Hospital Center, a 900-bed urban tertiary care and trauma center. He is an Associate Professor in the Georgetown University Department of Urology and participates actively in resident training. Over his 7 years in Washington, he has developed the Reconstructive Unit into a referral center for complex genitourinary reconstruction and prosthetics throughout the Mid-Atlantic Region. He has had his work presented at the regional, national and international level, and has co-authored a number of publications in the urologic reconstruction subspecialty.
William Goeren, MSW, OSW-C, LCSW-R
Clinical Program Director,CancerCare, New York.
Bill Goren is the Director of Clinical Programs at CancerCare. Prior to his work at CancerCare, William was the Director of Mental Health for the AIDS Healthcare Foundation in Los Angeles, and, in 1994, opened the first Gilda’s Club in New York City. He is the co-author of the chapter “Unique Issues Confronting Gay, Lesbian, and Bisexual Individuals Diagnosed with Cancer” for the Oxford University Press Handbook of Oncology Social Work and the author of the chapter Social Work, HIV Disease, and Palliative Care” for the Oxford Textbook of Palliative Social Work.
Resources
- Link to the Feb. 27, 2020 webinar archive
- PowerPoint deck from the presentation
- Prostate Cancer handout from Boston Scientific - PDF
Webinar: Genetic Testing and Genetic Counseling in Prostate Cancer
Recorded May 09, 2018
Sponsored by Myriad Genetics
Dr. Leonard G. Gomella, Chair of the Urology Department at the Kimmel Cancer Center Network of Jefferson Medical College will be presenting on "Genetic Testing and Genetic Counseling in Prostate Cancer".
Resources
- Link to the May 9, 2018 webinar archive recording.
- Presentation slides - May 9, 2018 - 1st deck - PDF.
- Presentation slides - may 9, 2018 2nd deck - PDF.
Determine your hereditary cancer risk
Myriad Genetics is offering a free heredity cancer quiz. This brief questionnaire will help you determine whether you should be further evaluated for Hereditary Breast and Ovarian Cancer syndrome, Lynch syndrome, or other hereditary cancers:
Use this link to access the free heredity cancer quiz...
AR-V7 Splice Variant and Treatment Choices in Prostate Cancer
Recorded - April 3, 2018 with Ryan Dittamore and Deb Davison
Ryan Dittamore of Epic Sciences and Deb Davison from Genomic Health present on “AR-V7 Splice Variant and Treatment Choices in Prostate Cancer.”
This webinar was provided through a generous donation from Genomic Health.
Tissue Based Biomarkers for Localized Prostate Cancer
January 30, 2018 - with Dr. Ashley Ross, M.D., Ph.D.
- PowerPoint slides from the Jan 30, 2018 event in PDF format
- Link to recorded webinar (coming soon)
Dr. Ross' presentation was provided through a generous donation from Genomic Health.
rev: 11/30/2023
 Ashley Ross - January 2018 | [ ] | 4094 kB |
| Ryan Dittamore and Deb Davison - April 2018 | [ ] | 5500 kB |
 Slideshow for Nov 28 webinar | [ ] | 972 kB |
| Article from Prostate Cancer and Prostatic Diseases | [ ] | 566 kB |